A Study of Nivolumab + Chemotherapy or Nivolumab + Ipilimumab Versus Chemotherapy in Patients With EGFR Mutation, T790M Negative NSCLC Who Have Failed 1L EGFR TKI Therapy

For more information regarding Bristol-Myers Squibb Clinical Trial participation, please
visit www.BMSStudyConnect.com

Inclusion Criteria:

- Confirmed stage IV or recurrent EGFR Mutation (MT)+ NSCLC with disease progression
after 1 prior EGFR TKI therapy

- No evidence of exon 20 T790M mutation after progression on prior EGFR tyrosine kinase
inhibitor(TKI) therapy.

- Measurable disease according to Response Evaluation Criteria in Solid Tumors version
1.1 (RECIST 1.1)

- Available tumor sample for Programmed death-ligand 1 (PD-L1) immunohistochemical (IHC)
and exon 20 T790M testing

Exclusion Criteria:

- Subjects with symptomatic central nervous system (CNS) metastases

- Subjects with carcinomatous meningitis

- Subjects with an active, known or suspected autoimmune disease are excluded

- Subjects with known SCLC transformation

Other protocol defined inclusion/exclusion criteria could apply